Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Canine Pericardial Effusion: Tamponade and Workup
Recognize tamponade, prioritize drainage, and interpret canine pericardial fluid cytology without mistaking a negative result for exclusion of cancer.
Read →Feline Hypertrophic Cardiomyopathy: ACVIM Staging, Diagnosis, and Evidence-Based Management
A clinician-facing evidence hub on feline HCM: ACVIM 2020 staging, echocardiographic diagnosis, clopidogrel-based thromboprophylaxis with the FAT CAT trial and its 2024 absolute-benefit re-analysis, acute FATE management, and emerging myosin-inhibitor and rapamycin therapies.
Read →Canine Dilated Cardiomyopathy: Hereditary DCM, Diet-Associated DCM, Preclinical Screening, and Evidence-Based Management
DCM affects up to 58% of Dobermans; annual Holter screening recommended from age 3. FDA grain-free/DCM investigation closed Dec 2022 without confirmed caus
Read →Pimobendan for Canine Myxomatous Mitral Valve Disease (MMVD): Evidence, Mechanism, and Use
Pimobendan's dual calcium-sensitizer and PDE3-inhibitor mechanism, the EPIC and QUEST pivotal trials, 2019 ACVIM staging, PROTECT DCM data, and the 2024-2026 reverse-remodeling evidence that says document baseline echo before you dose a Stage B2 dog.
Read →Rapamycin (Sirolimus) for Feline Hypertrophic Cardiomyopathy: RAPACAT Trial, Evidence, and Safety
The RAPACAT RCT showed low-dose delayed-release rapamycin significantly reduced LV wall-thickness progression in subclinical feline HCM at Day 180 (P=0.01), with mechanistic and ex vivo platelet-safety data now folded into one evergreen clinical reference.
Read →